Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $1,037.33

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have earned a consensus rating of “Moderate Buy” from the twenty-three analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, fifteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $1,032.57.

Several equities analysts have recently commented on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Leerink Partners restated a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Evercore ISI reduced their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $703.43 on Monday. The business’s 50-day simple moving average is $746.43 and its two-hundred day simple moving average is $956.18. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $666.25 and a 52 week high of $1,211.20. The stock has a market cap of $77.30 billion, a PE ratio of 17.41, a P/E/G ratio of 2.19 and a beta of 0.10.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. lifted its holdings in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the last quarter. Trust Co. of Vermont raised its holdings in Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 12 shares during the period. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company’s stock worth $967,000 after acquiring an additional 14 shares during the last quarter. Finally, Nvwm LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 14 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.